Todd Schwarzinger joined the Cleveland Clinic in January 2022 as General Manager, Business Development and Licensing for Cleveland Clinic Innovations where he leads the business development and partnering efforts for Cleveland Clinic’s deep portfolio of innovative technologies. Todd joined the Cleveland Clinic with over 20 years of innovation leadership, investment banking, investing and consulting experience in healthcare and life sciences.
Prior to joining the Cleveland Clinic, Todd led the launch of the Veale Institute for Entrepreneurship at Case Western Reserve University, where he served as Chief Commercialization Officer, and served as a Venture Partner with Refinery Ventures. Todd also served as a Managing Director and head of the Life Sciences and Healthcare practice at Silicon Valley Bank (SVB) for the Bay Area and Pacific Northwest. Todd and his team focused on lending, banking, and relationship solutions for healthcare clients of all life stages spanning biopharma, medical device, digital health, diagnostics and life science tools.
Prior to joining SVB, Todd was an Executive Director in the healthcare investment banking division at Morgan Stanley where he advised a broad range of medical device and biopharmaceutical clients on mergers and acquisitions, initial public offerings, the equity and debt capital markets. In his nearly nine year career at Morgan Stanley across both London and New York, he was responsible for life sciences M&A transactions totaling over $5 billion and raised over $3 billion in capital markets transactions spanning North America, Europe and Asia.
Todd serves on the board of Cleveland Clinic portfolio companies Centerline Biomedical and Method AI.
Todd holds a bachelor’s in Finance from Miami University and received his MBA from the Fuqua School of Business at Duke University.